Characterizing the Molecular Mechanisms of PRSS56-Dependent Ocular Growth and Refractive Error
表征 PRSS56 依赖性眼生长和屈光不正的分子机制
基本信息
- 批准号:10367868
- 负责人:
- 金额:$ 40.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAnimal ModelAttentionBiochemicalBlindnessCallithrixCell Culture TechniquesCell physiologyClinicalCuesDefectDeletion MutationDependovirusDevelopmentDiseaseEnsureExtracellular MatrixEyeGene TargetingGeneticGenetic ProcessesGenetic studyGlaucomaGoalsGrowthGrowth FactorHumanHyperopiaImageIndividualInterventionInvestigationLengthLinkMacular degenerationMediatingMediator of activation proteinMessenger RNAMicrophthalmosModernizationMolecularMolecular GeneticsMuller&aposs cellMusMutant Strains MiceMutationMyopiaOpticsPathogenesisPathway interactionsPrevalenceProcessProteomicsPublic HealthRefractive ErrorsRegulationRetinaRetinal DetachmentRiskRoleScleraSeriesSerine ProteaseSerine Proteinase InhibitorsSignal TransductionStructure of retinal pigment epitheliumTestingTimeTransgenic OrganismsTranslatingVariantVisionVisualWNT Signaling Pathwaybeta catenincell typeconditional mutantdeprivationemmetropizationexperimental studyfallsgenetic approachinsightlensmouse modelnew therapeutic targetoverexpressionpostnatalpostnatal developmentprenatalpreventprogramsresponsetargeted treatmenttherapeutic targettrypsin-like serine protease
项目摘要
Abstract
Refractive errors are a major cause of vision loss worldwide, and the rising prevalence of myopia and
associated blinding conditions is a significant public health concern. Regulation of ocular axial growth is critical
for normal refractive development to ensure that a focused image falls directly on the retina. Our goal is to
decode the molecular and genetic program that governs ocular axial growth. Ocular growth is driven by an
intrinsic, genetic process during prenatal and postnatal development (vision-unadjusted) and by a postnatal,
vision-guided process, emmetropization, thought to interact with intrinsic ocular growth such that the eye's
axial length matches its optical power. Enhanced intrinsic ocular growth and defective emmetropization are
thought to cause a mismatch between ocular axial length and optical power, leading to myopia. Ocular axial
growth relies on signals from the retina to the sclera to promote extracellular matrix remodeling and ocular
elongation. However, the mechanisms by which the signals translate to ocular axial growth remain elusive. Our
studies suggest that PRSS56, a secreted serine protease, is a component of the intrinsic machinery that
supports ocular axial growth. However, it is not known whether Prss56 has a direct role in emmetropization.
We propose to uncover the molecular and cellular processes underlying PRSS56-dependent refractive
development and associated errors and assess the role of PRSS56 in vision-guided ocular growth.
Despite evidence that altered expression of PRSS56 affects ocular axial length, the factors that regulate its
expression and mediate its effect are not known. The Wnt-mediated pathway is associated with myopia
pathogenesis, and we have found that Prss56 responds to Wnt signaling agonists. In Aim 1, we will elucidate
the link between Wnt and Prss56 by modulating WNT activity in genetic mouse models and studying the effect
on the retinal expression of PRSS56 and ocular growth (Aim 1.1). We will also determine, in conditional mouse
models, whether retinal pigment epithelium–localized Serpine3—which we identified as a candidate mediator
of PRSS56-dependent growth—helps relay PRSS56-dependent signals that support ocular growth (Aim 1.2).
In Aim 2, we will characterize the function of PRSS56 to guide the identification of its substrate(s) and targeted
therapies. In Aim 3, we will test the role of PRSS56 in emmetropization and PRSS56-dependent regulation of
ocular axial growth by temporarily inactivating PRSS56 in conditional mutant mice and using experimental
paradigms that induce axial elongation in response to visual blur or optical defocus.
The proposed studies will provide a molecular and genetic framework to understand the mechanisms of ocular
growth and guide us to potential therapeutic targets to manage myopia.
摘要
屈光不正是全世界视力丧失的主要原因,近视和近视眼的患病率不断上升,
相关的致盲条件是一个重要的公共卫生问题。调节眼轴生长至关重要
以确保聚焦图像福尔斯直接落在视网膜上。我们的目标是
解码控制眼轴生长的分子和遗传程序。眼睛的生长是由
内在的,遗传过程在产前和产后发展(视力未调整)和产后,
视觉引导过程、正视化,被认为与眼睛内在生长相互作用,使得眼睛的
轴向长度匹配其光功率。增强的内在眼生长和缺陷的正视化是
被认为会导致眼轴长度和屈光力之间的不匹配,从而导致近视。眼轴
生长依赖于从视网膜到巩膜的信号,以促进细胞外基质重塑和眼内分泌。
伸长率然而,这些信号转化为眼轴生长的机制仍然难以捉摸。我们
研究表明,PRSS 56是一种分泌型丝氨酸蛋白酶,是内在机制的组成部分,
支持眼轴生长。然而,尚不清楚Prss 56是否在正视化中具有直接作用。
我们建议揭示PRSS 56依赖性屈光不正的分子和细胞过程,
发展和相关的错误,并评估PRSS 56在视觉引导的眼睛生长的作用。
尽管有证据表明PRSS 56的表达改变会影响眼轴长度,但调节其表达的因素仍然存在。
表达和介导其作用尚不清楚。Wnt介导的通路与近视相关
我们已经发现Prss 56对Wnt信号传导激动剂有应答。在目标1中,我们将阐明
通过在遗传小鼠模型中调节Wnt活性并研究其作用,
对视网膜PRSS 56表达和眼生长的影响(目的1.1)。我们还将确定,在条件鼠标
模型,无论是视网膜色素上皮定位丝氨酸3-我们确定为候选调解人
PRSS 56依赖性生长的蛋白质-帮助传递PRSS 56依赖性信号,支持眼生长(目标1.2)。
在目标2中,我们将描述PRSS 56的功能,以指导其底物的鉴定和靶向
治疗在目标3中,我们将测试PRSS 56在正视化中的作用和PRSS 56依赖性调节。
通过暂时失活PRSS 56在条件突变小鼠中的眼轴生长和使用实验
这些范例响应于视觉模糊或光学散焦而引起轴向伸长。
这些研究将为理解眼内营养不良的发生机制提供分子和遗传学框架。
生长和指导我们潜在的治疗目标,以管理近视。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kayarat Saidas Nair其他文献
Kayarat Saidas Nair的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kayarat Saidas Nair', 18)}}的其他基金
Characterizing the Molecular Mechanisms of PRSS56-Dependent Ocular Growth and Refractive Error
表征 PRSS56 依赖性眼生长和屈光不正的分子机制
- 批准号:
10705558 - 财政年份:2022
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular Mechanisms of Human Glaucoma Genes
确定人类青光眼基因的分子机制
- 批准号:
10444972 - 财政年份:2022
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular Mechanisms of Human Glaucoma Genes
确定人类青光眼基因的分子机制
- 批准号:
10612930 - 财政年份:2022
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
9211347 - 财政年份:2014
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8788029 - 财政年份:2014
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8784082 - 财政年份:2014
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
9003054 - 财政年份:2014
- 资助金额:
$ 40.38万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8418312 - 财政年份:2013
- 资助金额:
$ 40.38万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 40.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 40.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)